Given the dramatically increasing rates of obesity prevalence and the resulting size of the potential market for treatment of diabetes — by surgery, drugs, devices or combinations of these — manufacturers of drugs and devices are working furiously to develop treatment options that can face an increasingly rigorous set of requirements by the FDA to gain approval. Even recent adverse regulatory decisions or market withdrawals of obesity drugs have not quelled the drive for more effective treatment options.
As a result, a number of specific market introductions and market success are expected to take place in the 2011 to 2019 time frame (we identify specific developments in the 2011 global obesity report). Much of the revenue expected by 2019 will come from newly introduced spanning drugs, combination drugs and devices.
See below for our estimate of the 2011 and 2019 breakdown of the obesity treatment market.
Source: "Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019," Report #S835.